2m 2m 2m 2m 2m 2m 2m
Fate Therapeutic (FATE)
NASDAQ
$2.52+$0.06 (+2.65%)
Price as of Aug 03, 2026 12:42 PM EDT- $285.6MMarket Cap
- 128.97%1-Year Change
- BiotechnologyIndustry
Fate Therapeutic (FATE)
$2.52+$0.06 (+2.65%)
FATE | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $2.45 | ||
Change | -$0.06 (-2.39%) | ||
Open | $2.51 | ||
High | $2.56 | ||
Low | $2.39 | ||
Previous Close | $2.51 | ||
Volume | 1,458,668 | ||
30-Day Average Volume | 2,614,692 | ||
1-Week Change | 1.66% | ||
1-Month Change | -9.26% | ||
1-Year Change | 128.97% | ||
3-Year Change | -40.68% | ||
5-Year Change | -97.04% | ||
Fundamentals | |||
Shares Outstanding | 116.6M | ||
Total Assets | $284.9M | ||
Market Cap | $285.6M | ||
Enterprise Value | $246.0M | ||
Period: QTR TTM FY | |||
Revenue | $1.3M | ||
Net Income | -$31.2M | ||
Free Cash Flow | -$31.1M | ||
EBIT | -$31.2M | ||
EBITDA | -$28.3M | ||
Net Working Capital | $148.8M | ||
EPS | -$0.26 | ||
Enterprise Value/EBITDA | -9 | ||
Enterprise Value/Revenue | 189 | ||
P/B | 2 | ||
P/E | -9 | ||
PEG | -2 | ||
Price/Free Cash Flow | -9 | ||
Price/Operating Cash Flow | -9 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue